ZOOM IN ON
YOUR OLDER
PATIENTS
THIS 2019
FLU SEASON
The on c l e y d
enhan vaccine
infl ue t n h z e a NIP for
on rs & over
65 ye n a 2019
i
• FLUAD, an MF59 adjuvanted influenza vaccine,
®
is tailored to help protect those aged 65 years and over
against influenza 2
*
• Adding MF59 adjuvant to the vaccine improves
the magnitude, breadth and persistence of the immune response,
compared with standard dose non-adjuvanted vaccines 2–4
1
influenza vaccine, adjuvanted
* Contains an adjuvant known to increase the immunogenicity of vaccines
2
For the 2019 FLUAD presentation, no natural rubber latex is present
2
®
Before prescribing, please review Product Information available at www.seqirus.com.au/PIs
MINIMUM PRODUCT INFORMATION. FLUAD Inactivated influenza vaccine (surface antigen), suspension for injection, adjuvanted. APPROVED INDICATION: Active immunisation against
influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications. CONTRAINDICATIONS: Hypersensitivity to eggs, chicken proteins,
kanamycin sulfate, neomycin sulfate, formaldehyde, or cetyltrimethylammonium bromide (CTAB), any constituent of the vaccine or in anyone who has had an anaph ylactoid reaction to previous
influenza vaccination. CLINICALLY SIGNIFICANT PRECAUTIONS: FLUAD should not be administered intravascularly or sub-cutaneously. As with all injectable vaccines, appropriate medical
treatment and supervision should always be readily available in case a rare anaphylactic event occurs following the administration of the vaccine. Pregnancy Category B2. If Guillain-Barré
Syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks. CLINICALLY
SIGNIFICANT INTERACTIONS: FLUAD must not be mixed with other preparations for injection. FLUAD may be given at the same time as other vaccines although no clinical data on
concomitant administration with other vaccines are available. Immunisation should be carried out on separate limbs. It should be noted that any adverse reactions might be intensified. VERY
COMMON AND COMMON ADVERSE EVENTS: Local reactions, including redness, swelling, induration, pain at the injection site and ecchymosis. Systemic reactions including fever, malaise,
shivering, fatigue, headache, sweating, myalgia, arthralgia. These reactions usually disappear within 1-2 days without treatment. DOSAGE AND USAGE: A single 0.5mL dose should be
administered by intramuscular injection into the deltoid muscle. Gently shake before use. After shaking, the normal appearance of FLUAD is a milky-white suspension. Based on Approved
Product Information, November 2018.
REFERENCES: 1. Chief Medical Officer statement: https://beta.health.gov.au/news-and-events/media-releases/2019-influenza-vaccines. Accessed 6th
March 2019. 2. FLUAD Approved Product Information. 3. DT O’Hagan et al. Expert Rev. Vaccines. 2013; 12(1):13–30. 4. Frey SE et al. Vaccine. 2014; 32:5027–5034.
Seqirus (Australia) Pty Ltd. ABN 66 120 398 067, 63 Poplar Road Parkville, Victoria 3052. www.seqirus.com.au. Medical Information: 1800 642 865.
FLUAD is a registered trademark and Seqirus is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: March 2019. SEQ/FTIV/0318/0006(1)e.
15378-210x297.
®
®
®
®
®
®
®
®
™
PBS Information: This product is listed on the National Immunisation Program (NIP) Schedule. Refer to the NIP schedule.